Compounded semaglutide and tirzepatide provided a vital stopgap during shortages, but their role has come under scrutiny as supply stabilizes. While affordability remains a pressing issue—particularly for those without insurance coverage—the risks of inconsistent quality, contamination, and adverse effects cannot be ignored. With pharmaceutical giants like Eli Lilly pushing for tighter restrictions and the FDA signaling a return to regulated channels, consumers face a pivotal choice. Injecting these medications demands confidence in their safety, and for now, the surest path lies with FDA-approved products. For those still drawn to compounded options, rigorous due diligence and medical oversight are non-negotiable steps to mitigate the gamble.

This is the official podcast of GLP-1 Tribe.  Find all the best resources about GLP-1 on the GLP-1 Tribe web site.
https://glp1tribe.com/